Kevin J. Harrington

72.3k total citations · 7 hit papers
768 papers, 31.6k citations indexed

About

Kevin J. Harrington is a scholar working on Oncology, Otorhinolaryngology and Genetics. According to data from OpenAlex, Kevin J. Harrington has authored 768 papers receiving a total of 31.6k indexed citations (citations by other indexed papers that have themselves been cited), including 323 papers in Oncology, 216 papers in Otorhinolaryngology and 202 papers in Genetics. Recurrent topics in Kevin J. Harrington's work include Head and Neck Cancer Studies (216 papers), Virus-based gene therapy research (192 papers) and Cancer Immunotherapy and Biomarkers (113 papers). Kevin J. Harrington is often cited by papers focused on Head and Neck Cancer Studies (216 papers), Virus-based gene therapy research (192 papers) and Cancer Immunotherapy and Biomarkers (113 papers). Kevin J. Harrington collaborates with scholars based in United Kingdom, United States and France. Kevin J. Harrington's co-authors include Alan Melcher, Richard G. Vile, Christopher M. Nutting, Hardev Pandha, Aadil Khan, Holly E. Barker, James Paget, Erik Sahai, Steven Hooper and Kate Newbold and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Kevin J. Harrington

742 papers receiving 31.0k citations

Hit Papers

The tumour microenvironment after radiotherapy: me... 2007 2026 2013 2019 2015 2011 2007 2013 2020 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
    2015 1.6k citations Holly E. Barker, Kevin J. Harrington et al. profile →
  2. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial
    2011 1.2k citations Christopher M. Nutting, Kevin J. Harrington et al. profile →
  3. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells
    2007 1.2k citations Kevin J. Harrington et al. profile →
  4. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts
    2013 1.1k citations Kevin J. Harrington et al. profile →
  5. Inflammatory microenvironment remodelling by tumour cells after radiotherapy
    2020 601 citations Martin McLaughlin, Malin Pedersen et al. profile →
  6. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
    2019 491 citations Ezra E.W. Cohen, Maura L. Gillison et al. profile →
  7. Optimizing oncolytic virotherapy in cancer treatment
    2019 384 citations Kevin J. Harrington et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kevin J. Harrington United Kingdom 85 13.5k 9.2k 7.7k 6.0k 5.0k 768 31.6k
Ralph R. Weichselbaum United States 107 18.7k 1.4× 17.9k 1.9× 3.3k 0.4× 10.6k 1.8× 9.4k 1.9× 707 48.4k
Robert L. Ferris United States 90 13.5k 1.0× 6.6k 0.7× 1.5k 0.2× 4.8k 0.8× 7.6k 1.5× 556 28.7k
Adel K. El‐Naggar United States 99 16.8k 1.2× 12.0k 1.3× 2.2k 0.3× 5.7k 0.9× 1.5k 0.3× 679 36.4k
Dong M. Shin United States 71 8.6k 0.6× 10.1k 1.1× 957 0.1× 5.2k 0.9× 1.3k 0.3× 361 26.7k
David Sidransky United States 121 25.6k 1.9× 40.0k 4.3× 5.2k 0.7× 9.6k 1.6× 2.7k 0.5× 576 66.1k
Suzanne L. Topalian United States 82 32.6k 2.4× 12.4k 1.3× 4.4k 0.6× 7.7k 1.3× 27.0k 5.4× 215 49.2k
Carolyn C. Compton United States 82 17.1k 1.3× 5.9k 0.6× 1.3k 0.2× 9.4k 1.6× 1.2k 0.2× 319 36.2k
Theresa L. Whiteside United States 107 13.8k 1.0× 16.6k 1.8× 1.5k 0.2× 2.3k 0.4× 20.3k 4.0× 607 39.4k
Jianfeng Xu United States 59 6.9k 0.5× 9.3k 1.0× 3.8k 0.5× 7.6k 1.3× 2.8k 0.6× 344 26.6k
Quynh‐Thu Le United States 79 7.8k 0.6× 6.7k 0.7× 521 0.1× 7.0k 1.2× 2.0k 0.4× 461 25.4k

Countries citing papers authored by Kevin J. Harrington

Since Specialization
Citations

This map shows the geographic impact of Kevin J. Harrington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin J. Harrington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin J. Harrington more than expected).

Fields of papers citing papers by Kevin J. Harrington

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin J. Harrington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin J. Harrington. The network helps show where Kevin J. Harrington may publish in the future.

Co-authorship network of co-authors of Kevin J. Harrington

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin J. Harrington. A scholar is included among the top collaborators of Kevin J. Harrington based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin J. Harrington. Kevin J. Harrington is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Simoes‐Sousa, Susana, Najaf Amin, Alison Harrod, et al.. (2025). ARID1A stabilizes non-homologous end joining factors at DNA breaks induced by the G4 ligand pyridostatin. Cell Reports. 44(9). 116277–116277.
2.
Seiwert, Tanguy Y., Sophie Wildsmith, Jérôme Fayette, et al.. (2024). Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma. Cancer Immunology Immunotherapy. 73(4). 70–70. 6 indexed citations
3.
Aymerich, Clàudia, Irene Braña, Antonio Rullan, et al.. (2024). A comprehensive examination of mental health in patients with head and neck cancer: systematic review and meta-analysis. JNCI Cancer Spectrum. 8(3). 12 indexed citations
4.
5.
6.
7.
Harrington, Kevin J., Anthony Kong, Nicolas Mach, et al.. (2020). Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clinical Cancer Research. 26(19). 5153–5161. 83 indexed citations
8.
Ferris, Robert L., Lisa Licitra, Jérôme Fayette, et al.. (2019). Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clinical Cancer Research. 25(17). 5221–5230. 115 indexed citations
9.
Annels, Nicola, David Mansfield, Carmen Ballesteros‐Merino, et al.. (2019). Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer. Clinical Cancer Research. 25(19). 5818–5831. 97 indexed citations
10.
Panek, Rafał, Liam Welsh, Maria A. Schmidt, et al.. (2017). Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI. Clinical Cancer Research. 23(15). 4233–4241. 32 indexed citations
11.
Dillon, Magnus T., Holly E. Barker, Malin Pedersen, et al.. (2016). Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei. Molecular Cancer Therapeutics. 16(1). 25–34. 82 indexed citations
12.
Taylor, Graham S., Hui Jia, Kevin J. Harrington, et al.. (2014). A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer. Clinical Cancer Research. 20(19). 5009–5022. 138 indexed citations
13.
Karapanagiotou, Eleni, Victoria Roulstone, Katie Twigger, et al.. (2012). Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies. Clinical Cancer Research. 18(7). 2080–2089. 151 indexed citations
14.
Touchefeu, Yann, Kevin J. Harrington, J. P. Galmiche, & Georges Vassaux. (2010). Review article: gene therapy, recent developments and future prospects in gastrointestinal oncology. Alimentary Pharmacology & Therapeutics. 32(8). 953–968. 30 indexed citations
15.
Harrington, Kevin J., Eleni Karapanagiotou, Victoria Roulstone, et al.. (2010). Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers. Clinical Cancer Research. 16(11). 3067–3077. 94 indexed citations
16.
Harrington, Kevin J., Iman El‐Hariry, Antoine Lusinchi, et al.. (2009). Phase I Study of Lapatinib in Combination With Chemoradiation in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology. 27(7). 1100–1107. 52 indexed citations
17.
Baril, Patrick, Sophie Conchon, Pilar Martín‐Duque, et al.. (2009). Targeted Radionuclide Therapy Using a Wnt-Targeted Replicating Adenovirus Encoding the Na/I Symporter. Clinical Cancer Research. 15(21). 6595–6601. 53 indexed citations
18.
Twigger, Katie, Laura Vidal, Christine L. White, et al.. (2008). Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy. Clinical Cancer Research. 14(3). 912–923. 88 indexed citations
19.
Hingorani, Mohan, Christine L. White, Martin Gore, et al.. (2008). Inhibition of Repair of Radiation-Induced DNA Damage Enhances Gene Expression from Replication-Defective Adenoviral Vectors. Cancer Research. 68(23). 9771–9778. 20 indexed citations
20.
Hingorani, Mohan, Christine L. White, Shane Zaidi, et al.. (2008). Radiation-Mediated Up-Regulation of Gene Expression from Replication-Defective Adenoviral Vectors: Implications for Sodium Iodide Symporter Gene Therapy. Clinical Cancer Research. 14(15). 4915–4924. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ralph R. Weichselbaum Breakdown of academic impact, for papers by Robert L. Ferris Breakdown of academic impact, for papers by Adel K. El‐Naggar Breakdown of academic impact, for papers by Dong M. Shin Breakdown of academic impact, for papers by David Sidransky Breakdown of academic impact, for papers by Suzanne L. Topalian Breakdown of academic impact, for papers by Carolyn C. Compton Breakdown of academic impact, for papers by Theresa L. Whiteside Breakdown of academic impact, for papers by Jianfeng Xu Breakdown of academic impact, for papers by Quynh‐Thu Le
Rankless by CCL
2026